All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Security
Security
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Updated Cochrane Review Finds Modest Prostate Cancer Mortality Reduction from PSA Screening, But Overdiagnosis Risks Remain

By

Megan Brooks

6h ago· 5 min readenNews

Summary

An updated Cochrane review finds that PSA screening probably reduces prostate cancer deaths by about 2 per 1000 men screened, a shift from the group's 2013 conclusion that screening did not significantly lower mortality. However, the modest benefit comes with increased diagnoses of localized cancers that may never become clinically significant, highlighting the ongoing trade-off between potential mortality reduction and overdiagnosis risks.

Source

Twitter / XUpdated Cochrane Review Finds Modest Prostate Cancer Mortality Reduction from PSA Screening, But Overdiagnosis Risks Remainmdsc.pe

Key quotes

· 3 pulled
PSA screening reduces prostate cancer deaths by about 2 per 1000 men screened
The new analysis, based on longer follow-up and additional trial data, suggests that PSA screening reduces prostate cancer deaths
This modest benefit comes at the cost of an increased number of prostate cancer diagnoses, many of which are localized cancers that may never have become clinically significant
Snippet from the RSS feed
New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.